国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Duvenhage virus Phosphoprotein (P) CSB-YP527553DMX
CSB-EP527553DMX
CSB-BP527553DMX
CSB-MP527553DMX
CSB-EP527553DMX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Spodoptera littoralis nuclear polyhedrosis virus Probable DNA-directed RNA polymerase subunit beta (LEF-8), partial CSB-YP527554FKR
CSB-EP527554FKR
CSB-BP527554FKR
CSB-MP527554FKR
CSB-EP527554FKR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vaccinia virus Protein F12 (MVA042L, ACAM3000_MVA_042), partial CSB-YP527555VEE
CSB-EP527555VEE
CSB-BP527555VEE
CSB-MP527555VEE
CSB-EP527555VEE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vaccinia virus Myristoylated protein G9 (MVA079R, ACAM3000_MVA_079), partial CSB-YP527556VEE1
CSB-EP527556VEE1
CSB-BP527556VEE1
CSB-MP527556VEE1
CSB-EP527556VEE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vaccinia virus Late protein H7 (MVA097R, ACAM3000_MVA_097), partial CSB-YP527557VEE1
CSB-EP527557VEE1
CSB-BP527557VEE1
CSB-MP527557VEE1
CSB-EP527557VEE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vaccinia virus Viral late gene transcription factor 2 (VLTF2) CSB-YP527558VEE
CSB-EP527558VEE
CSB-BP527558VEE
CSB-MP527558VEE
CSB-EP527558VEE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vaccinia virus Holliday junction resolvase (MVA133R, ACAM3000_MVA_133) CSB-YP527559VEE
CSB-EP527559VEE
CSB-BP527559VEE
CSB-MP527559VEE
CSB-EP527559VEE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vaccinia virus Serine/threonine-protein kinase 1 (VPK1) CSB-YP527560VEE
CSB-EP527560VEE
CSB-BP527560VEE
CSB-MP527560VEE
CSB-EP527560VEE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Sendai virus Nucleoprotein (N), partial CSB-YP527561SYH
CSB-EP527561SYH
CSB-BP527561SYH
CSB-MP527561SYH
CSB-EP527561SYH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis CUGBP Elav-like family member 1-A (cugbp1-a) CSB-YP527562XBE
CSB-EP527562XBE
CSB-BP527562XBE
CSB-MP527562XBE
CSB-EP527562XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Melanopsin-B (opn4b), partial CSB-YP527563XBE1
CSB-EP527563XBE1
CSB-BP527563XBE1
CSB-MP527563XBE1
CSB-EP527563XBE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Danio rerio Dorsal-ventral patterning tolloid-like protein 1 (tll1), partial CSB-YP527564DIL
CSB-EP527564DIL
CSB-BP527564DIL
CSB-MP527564DIL
CSB-EP527564DIL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chicken Podocalyxin (PODXL), partial CSB-YP527565CH
CSB-EP527565CH
CSB-BP527565CH
CSB-MP527565CH
CSB-EP527565CH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Protobothrops flavoviridis Phospholipase A2 inhibitor 1 CSB-YP527566EZB
CSB-EP527566EZB
CSB-BP527566EZB
CSB-MP527566EZB
CSB-EP527566EZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Probable tRNA threonylcarbamoyladenosine biosynthesis protein KAE1 homolog (PH1987) CSB-YP527567FHX
CSB-EP527567FHX
CSB-BP527567FHX
CSB-MP527567FHX
CSB-EP527567FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii V-type ATP synthase beta chain (atpB) CSB-YP527568FHX
CSB-EP527568FHX
CSB-BP527568FHX
CSB-MP527568FHX
CSB-EP527568FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii L-aspartate oxidase (nadB) CSB-YP527569FHX
CSB-BP527569FHX
CSB-MP527569FHX
CSB-EP527569FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii UPF0215 protein PH0071 (PH0071) CSB-YP527570FHX
CSB-EP527570FHX
CSB-BP527570FHX
CSB-MP527570FHX
CSB-EP527570FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Uncharacterized HTH-type transcriptional regulator PH0045 (PH0045) CSB-YP527571FHX
CSB-EP527571FHX
CSB-BP527571FHX
CSB-MP527571FHX
CSB-EP527571FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus horikoshii Alanyl-tRNA editing protein AlaX-M (alaXM) CSB-YP527572FHX
CSB-EP527572FHX
CSB-BP527572FHX
CSB-MP527572FHX
CSB-EP527572FHX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>